Compass Pathways (NASDAQ: CMPS) is moving closer to a potential commercial launch of its psilocybin-based depression treatment, and the company’s latest quarterly results suggest regulators may be accelerating the process.

‍

The biggest development from Q1 2026 wasn’t the financials. It was the regulatory momentum surrounding COMP360, the company’s synthetic psilocybin therapy for treatment-resistant depression.

‍

The FDA granted Compass a rolling New Drug Application submission and review process following positive Phase 3 trial data. The company also received a Commissioner’s National Priority Review Voucher, which could potentially shorten the FDA review timeline to as little as one to two months after final submission.

‍

‍

Compass still expects final NDA submission in Q4 2026, with management saying the company plans to be commercially launch-ready by year-end.

The company says more than 1,000 participants have now been involved across its Phase 3 program, with prior studies showing statistically significant improvements in treatment-resistant depression patients receiving COMP360. Additional 26-week data from the COMP006 trial are expected in early Q3 2026.

‍

‍

The numbers look good

‍

Financially, Compass appears far better positioned than many small biotech firms approaching commercialization.

‍

The company ended Q1 with roughly $466 million in cash and cash equivalents, compared to approximately $150 million at the end of 2025. Management says current cash reserves should fund operations into 2028.

‍

Research and development expenses declined to $26.5 million during the quarter, down from $30.9 million a year earlier, as Phase 3 development costs begin moderating. General and administrative expenses also fell to $16.4 million.

‍

The headline profit number requires some caution, though.

‍

Compass reported Q1 net income of $91.2 million, but that was primarily driven by a non-cash $130.9 million gain tied to warrant liabilities rather than core operations. Operationally, the company still posted a loss from operations of roughly $42.9 million.

‍

Investors also continue debating the broader commercial opportunity for psychedelic-assisted therapies.

‍

Compass believes COMP360 could fit within an existing network of more than 7,300 treatment centers already capable of handling multi-hour therapies. The company is also actively building commercial infrastructure, including physician education programs, payer engagement efforts, and treatment-center partnerships ahead of potential approval.

‍

For now, Compass Pathways remains a highly speculative biotech company. But unlike many early-stage psychedelic firms, it now has late-stage clinical data, a substantial cash runway, and what appears to be an increasingly cooperative regulatory environment.

‍